The Mark Foundation for Cancer Research(MFCR) shared a post on X:
“In Cell, Endeavor Awardees Scott Lowe and Michel Sadelain identify a CAR T target that effectively attacks both primary and metastatic tumors across a diverse range of cancer types.”
Title: A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Authors: Zeda Zhang, Yu-Jui Ho, Xin Fang, Minseo Kim, Marguerite Li, Wei Luan, Clemens Hinterleitner, Sascha Haubner, Friederike Kogel, Edwin C. Pratt, Elif Ozcelik, José Reyes, Qingwen Jiang, Vincent W. Yang, Yu-Jung Chen, Tao Wang, Haijiao Liu, Haonan Hu, Xueqian Zhuang, Jin Park, Stella V. Paffenholz, Kevin Chen, Qing Chang, Amanda Kulick, Jing Zhang, Eric Chan, Eric Rosiek, Ning Fan, Riley A. Williams, Adam C. Wang, Samuel Freeman, Sha Tian, Gertrude Gunset, Andreina Garcia Angus, Nicolas Lecomte, Selma Yeni Yildirim, Emily Ali, Michelle Wu, Ileana C. Miranda, Cristina R. Antonescu, Olca Basturk, Zeynep Tarcan, Natasha Rekhtman, Christina Wilson, Merve Basar, Jennifer L. Sauter, Hikmat A. Al-Ahmadie, Samuel Singer, Christine Iacobuzio-Donahue, Charles Rudin, Elisa de Stanchina, Karuna Ganesh, Paul B. Romesser, Britta Weigelt, Dan Dongeun Huh, Josef Leibold, Judith Feucht, Ignacio Vázquez-García, Matthew J. Bott, Dmitriy Zamarin, Sohrab P. Shah, Jason S. Lewis, Corina Amor, Dana Pe’er, Jorge Mansilla-Soto, Aveline Filliol, Michel Sadelain, Scott W. Lowe
Read the Full Article.
Other articles about The Mark Foundation for Cancer Research on OncoDaily.